A ONCE-WEEKLY GLP-1 RA
Regular self-monitoring of blood glucose to adjust the dose of Ozempic® is not required
When used in combination with a sulfonylurea or basal insulin, there was an increased risk of hypoglycemia with co-administered Ozempic®
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin when starting treatment with Ozempic®
When Ozempic® 1 mg was added to an SGLT2i, severe or BG-confirmed hypoglycemia occurred in 2.7% of patients and documented symptomatic hypoglycemia occurred in 5.3% of patients, compared to none in the placebo-treated group
In a 2-year CVOT that investigated 3,297 patients with T2DM, an imbalance in diabetic retinopathy complications was observed in patients with a history of diabetic retinopathy (3% with Ozempic® vs. 1.8% with placebo)
In clinical trials up to 1 year involving 4,807 patients with T2DM, adverse events related to diabetic retinopathy were reported in similar proportions of patients treated with Ozempic® (1.7%) and comparators (2.0%)
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy
In alignment with Diabetes Canada Guidelines, patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy2,25
BG, blood glucose; CVOT, cardiovascular outcome trial; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2DM, type 2 diabetes mellitus.
Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:
Novo Nordisk Canada Inc.
101-2476 Argentia Road
Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST
Main fax number:
Toll-free fax number: